ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)
Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in San Diego, numerous studies on MDS were presented, showcasing significant progress in the treatment and prognostic evaluation of low-risk MDS. Oncology Frontier - Hematology Frontier invited Dr. Huaquan Wang from Tianjin Medical University General Hospital to provide expert commentary on the most impactful research in this field, delivering cutting-edge insights to our readers.









